24 Feb VARIATION Study: Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy
VARIATION is a prospective multi-centre Irish study aiming to determine the impact of IBD and various medications for treatment of IBD on antibody responses to vaccination against COVID-19.
Patients with IBD (n=270) and healthy controls (n=116) were recruited prospectively and quantitative antibody responses assessed following COVID-19 vaccination. The impact of IBD and medications for treatment of IBD on vaccine response rates was investigated.
Initial results show patients with IBD have attenuated(reduced) serological responses to SARS-CoV-2 vaccination. Use of anti-TNF therapy negatively impacts anti-SP IgG levels further. Patients who do not seroconvert post-vaccination are a particularly vulnerable cohort. Impaired responses to vaccination in our study highlight the importance of booster vaccination programmes for patients with IBD.
Molecular Biomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection study In Crohn's disease patients
Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) is an international, pediatric and adult database to monitor and report on
STEIG: Stelara Treatment Effectiveness in Irish Gastroenterology
STEIG is a retrospective study of clinical outcomes of off licence treatment with Ustekinumab for